Efficacy and safety of intravenous antibiotics combined with inhalation of amikacin versus intravenous antibiotics for treatment of ventilator-associated pneumonia: a systematic review and meta-analysis

Chuxin Huang, Xiaona Zhan, J. Su, Changxi Miao, Jiamin Yao, Yuechun Lin, Luqian Zhou
{"title":"Efficacy and safety of intravenous antibiotics combined with inhalation of amikacin versus intravenous antibiotics for treatment of ventilator-associated pneumonia: a systematic review and meta-analysis","authors":"Chuxin Huang, Xiaona Zhan, J. Su, Changxi Miao, Jiamin Yao, Yuechun Lin, Luqian Zhou","doi":"10.3760/CMA.J.CN131368-20190429-00659","DOIUrl":null,"url":null,"abstract":"Objective \nReviewing and integrating published literature at home and abroad by meta-analysis to compare the efficacy and safety of aerosolized amikacin for treatment of ventilator-associated pneumonia (VAP). \n \n \nMethods \nComprehensive searches were performed from the PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, VIP, China national knowledge internet and Wanfang database to acquire randomized controlled trials (RCTs) comparing intravenous antibiotics combined with inhalation of amikacin treatment with intravenous antibiotics and the data were collected from the time of establishment of databases to November 2018.The methodological quality of the included studies were assessed following the preferred reporting items for systematic reviews and meta-analysis guidelines.Statistical analysis on the data was performed by RevMan 5.3 software. \n \n \nResults \nTotally eight RCTs were included in the meta-analysis.Pooled analysis showed that compared to the intravenous antibiotics, intravenous antibiotics combined with inhalation of amikacin treatment significantly improved the clinical cure rate (OR=2.59, 95% CI: 1.87-3.59, P<0.000 01), bacterial clearance rate (OR=2.87, 95% CI: 1.93-4.27, P<0.000 01), and weaning rate (OR=1.88, 95%CI: 1.16-3.04, P=0.01). The death rate (OR=1.39, 95%CI: 0.86-2.24, P=0.18), the happening of bronchospasm (OR=2.30, 95%CI: 1.00-5.30, P=0.05) and renal dysfunction rate (OR=0.61, 95%CI: 0.34-1.11, P=0.10) were not significantly different for intravenous antibiotics combined with inhalation of amikacin versus intravenous antibiotics. \n \n \nConclusions \nPatients with VAP received higher rate of clinical cure rate, bacterial clearance rate, and weaning rate and by using intravenous antibiotics combined with inhalation of amikacin treatment, whereas could not reduce the rate of mortality and didn′t increase the happening of bronchospasm and renal dysfunction rate. \n \n \nKey words: \nPneumonia, ventilator-associated; Meta-analysis; Inhalation; Amikacin; Intravenous antibiotics","PeriodicalId":10004,"journal":{"name":"Chinese Journal of Asthma","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2020-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Chinese Journal of Asthma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/CMA.J.CN131368-20190429-00659","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Objective Reviewing and integrating published literature at home and abroad by meta-analysis to compare the efficacy and safety of aerosolized amikacin for treatment of ventilator-associated pneumonia (VAP). Methods Comprehensive searches were performed from the PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, VIP, China national knowledge internet and Wanfang database to acquire randomized controlled trials (RCTs) comparing intravenous antibiotics combined with inhalation of amikacin treatment with intravenous antibiotics and the data were collected from the time of establishment of databases to November 2018.The methodological quality of the included studies were assessed following the preferred reporting items for systematic reviews and meta-analysis guidelines.Statistical analysis on the data was performed by RevMan 5.3 software. Results Totally eight RCTs were included in the meta-analysis.Pooled analysis showed that compared to the intravenous antibiotics, intravenous antibiotics combined with inhalation of amikacin treatment significantly improved the clinical cure rate (OR=2.59, 95% CI: 1.87-3.59, P<0.000 01), bacterial clearance rate (OR=2.87, 95% CI: 1.93-4.27, P<0.000 01), and weaning rate (OR=1.88, 95%CI: 1.16-3.04, P=0.01). The death rate (OR=1.39, 95%CI: 0.86-2.24, P=0.18), the happening of bronchospasm (OR=2.30, 95%CI: 1.00-5.30, P=0.05) and renal dysfunction rate (OR=0.61, 95%CI: 0.34-1.11, P=0.10) were not significantly different for intravenous antibiotics combined with inhalation of amikacin versus intravenous antibiotics. Conclusions Patients with VAP received higher rate of clinical cure rate, bacterial clearance rate, and weaning rate and by using intravenous antibiotics combined with inhalation of amikacin treatment, whereas could not reduce the rate of mortality and didn′t increase the happening of bronchospasm and renal dysfunction rate. Key words: Pneumonia, ventilator-associated; Meta-analysis; Inhalation; Amikacin; Intravenous antibiotics
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
静脉注射抗生素联合吸入阿米卡星与静脉注射抗生素治疗呼吸机相关性肺炎的疗效和安全性:一项系统回顾和荟萃分析
目的通过荟萃分析对国内外已发表文献进行梳理和整合,比较雾化阿米卡星治疗呼吸机相关性肺炎(VAP)的疗效和安全性。方法综合检索PubMed、Embase、Cochrane中央对照试验注册库、Web of Science、VIP、中国国家知识网、万方数据库,获取静脉抗生素联合吸入阿米卡星治疗与静脉抗生素比较的随机对照试验(RCTs),数据采集自建库时至2018年11月。纳入研究的方法学质量按照系统评价和荟萃分析指南的首选报告项目进行评估。采用RevMan 5.3软件对数据进行统计分析。结果meta分析共纳入8项rct。合并分析显示,与静脉注射抗生素相比,静脉注射抗生素联合吸入阿米卡星治疗显著提高了患儿的临床治愈率(OR=2.59, 95%CI: 1.87 ~ 3.59, P< 0.0001)、细菌清除率(OR=2.87, 95%CI: 1.93 ~ 4.27, P< 0.0001)和脱机率(OR=1.88, 95%CI: 1.16 ~ 3.04, P=0.01)。静脉注射抗生素联合吸入阿米卡星与静脉注射抗生素的死亡率(OR=1.39, 95%CI: 0.86 ~ 2.24, P=0.18)、支气管痉挛发生率(OR=2.30, 95%CI: 1.00 ~ 5.30, P=0.05)、肾功能不全发生率(OR=0.61, 95%CI: 0.34 ~ 1.11, P=0.10)差异无统计学意义。结论VAP患者临床治愈率、细菌清除率、脱机率较高,静脉应用抗生素联合吸入阿米卡星治疗,但不能降低病死率,且未增加支气管痉挛的发生和肾功能不全率。关键词:肺炎;呼吸机相关性;荟萃分析;吸入;阿米卡星;静脉注射抗生素
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Research progress of obstructive sleep apneahypopnea syndrome and coronary heart disease The relationship between obstructive sleep apnea and optic neuropathy Correlationship between oxidative damage and IP-10, Rantes in lung cancer patients Correlation between NADPH oxidase 4 and epithelial mesenchymal transformation in non-small cell lung cancer Efficacy and safety of intravenous antibiotics combined with inhalation of amikacin versus intravenous antibiotics for treatment of ventilator-associated pneumonia: a systematic review and meta-analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1